Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 7Prostatic Neoplasms 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Thyroid Nodule 1Thyroid Neoplasms 1Thyroid Diseases 1Skin Neoplasms 1Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 171Paclitaxel 129Radiotherapy 119Cisplatin 109Docetaxel 93Gemcitabine 81Erlotinib Hydrochloride 80Pemetrexed 78Bevacizumab 56Etoposide 41pembrolizumab 36Gefitinib 32Vinorelbine 31Topotecan 30Surveys and Questionnaires 29Irinotecan 28Radiosurgery 21Nivolumab 20Drug Therapy 20Magnetic Resonance Spectroscopy 18Cetuximab 18durvalumab 17Early Intervention, Educational 17Blood Specimen Collection 17Surgical Procedures, Operative 16Cyclophosphamide 16Celecoxib 15Ipilimumab 14Immunohistochemistry 14Filgrastim 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lung Neoplasms × Biopsy, Needle × Clear all
NCT00673569 2010-08-09

Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
40 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡